GT719 injection for people with moderate to severe refractory autoimmune disease.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm, open-label early phase 1 trial with dose-escalation and expansion cohorts enrolling 30 participants. Adult patients with moderate to severe refractory autoimmune disease — including specified systemic lupus erythematosus and antibody-positive idiopathic inflammatory myopathy cases — will receive GT719 injections and be monitored for safety, clinical response, and cellular pharmacokinetics. The trial will collect clinical disease activity measures and laboratory data over defined follow-up visits to characterize tolerability and early signs of efficacy. Results will inform dosing and feasibility for later-stage studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Voluntarily enrolled in the study, signed an informed consent form, willing and able to comply with the study protocol.
* 2\. Aged 18 to 65 years (inclusive), regardless of gender.

Specific inclusion criteria:

* 3\. Participants with systemic lupus erythematosus (SLE)

  1. Meets the classification criteria for SLE in the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR);
  2. Disease activity score SLEDAI-2000 ≥ 6, with at least one British Islet Lupus Assessment Group Index (BILAG-2004) Grade A (severe manifestations) or two Grade B (moderate manifestations) organ scores, or both; Or the disease activity score SLEDAI-2000 ≥ 8;
* 4\. Participants with idiopathic inflammatory myopathy （IIM）

  1. Complies with the 2017 EULAR/ACR classification criteria for inflammatory myopathy (including DM, PM, ASS, and NM)
  2. Myositis antibody positive;
  3. . Meets the definition of recurrence, refractory or progressive;
* 5\. Participants with systemic sclerosis

  1. . Meet the 2013 American College of Rheumatology (ACR) SSc criteria;
  2. . SSc related antibodies are positive;
  3. . Meets the definition of refractory or progressive recurrence

Exclusion Criteria:

* 1\. Within 3 weeks prior to lymphodepleting chemotherapy, complement inhibition therapy (such as Ecuzumab) has been used;
* 2\. Received attenuated live vaccine within 4 weeks before lymphodepleting chemotherapy;
* 3\. Having undergone major surgery within the 8 weeks prior to screening, or planning to undergo surgery during the study period;
* 4\. Medical history of organ transplantation;
* 5\. Previously received CAR-T product therapy targeting any target (excluding GT719 therapy);
* 6\. According to the investigator's judgment, the situations that hinder participants from participating in the entire trial, confound the trial results, or participate in the trial that are not in the best interests of the participants.

Where it's running

• Affiliated Hospital of Nantong University
  Nantong, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Zhifeng Gu
• Email: guzhifeng@126.com
• Phone: 086-13706291941

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Autoimmune neurological diseases and neurotoxicity after immunotherapy: uncovering immune attack mechanisms

  This study tests why some cancer patients who receive immune checkpoint inhibitors develop neurological symptoms by examining their blood and spinal fluid for immune clues.

  Recruiting at 3 sites Assistance Publique - Hôpitaux de Paris · Le Kremlin-Bicêtre and 3 other locations · NCT07456358

• GR1803 for systemic lupus erythematosus (SLE)

  This trial will test GR1803 injections in people with active systemic lupus (SLE) to see if the drug is safe and helps control lupus symptoms.

  Recruiting Phase 1/2 Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Wuhan, Hubei · NCT07348055

• Evaluating the role of autoantibodies in autoimmune hepatitis severity

  This study is trying to see if certain autoantibodies in the blood can help us understand how severe autoimmune hepatitis is in patients.

  Recruiting Centre Hospitalier Universitaire de la Guadeloupe · Paris, France and 1 other locations · NCT06761209

• Joint tissue analysis to understand rare and immunotherapy-related inflammatory arthritis

  This project tests whether analyzing joint biopsy tissue can reveal distinct immune features in adults with inflammatory arthritis linked to rare autoimmune diseases or caused by cancer immunotherapy.

  Recruiting University Hospital, Brest · Bordeaux and 1 other locations · NCT07302074

• ACE Reno Pico Cell Matrix for reducing proteinuria and supporting kidney function

  This trial will test whether taking ACE Reno, a sublingual peptide solution four times daily for 12 weeks, can lower urine protein and help stabilize kidney function in adults with nephropathy or chronic kidney disease.

  Recruiting Phase 4 Ace Cells Lab Limited · Giza, GZ · NCT07187713

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.